Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Dapagliflozin 10 mg
NCT06127212Phase 1Completed
- Sponsor
- Dexa Medica
- Start
- Mar 2023
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Dexa Medica. Primary endpoints: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Measurable Concentration at 48 hours and Maximum Plasma Concentration at 48 hours. Started Mar 2023; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06127212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127212.